Bart Deplancke Email & Phone Number

Bart Deplancke graduated as a Biochemical Engineer at Ghent University (Belgium, 1998) after which he pursued doctoral studies in Immunobiology at the University of Illinois (USA) and postdoctoral work in regulatory genomics at the Harvard and UMass Medical Schools. In 2007, he established his lab at the EPFL School of Life Sciences where he is now a Full Professor and Vice-Dean of Innovation and is developing new, often single cell-related technologies to study how genomic variation mediates phenotypic diversity, especially in a metabolic context. These efforts allowed his group to for example discover a new anti-adipogenic stromal cell type as well as a new genomic concept, chromatin modules, that rationalize gene regulation in 3D. In 2013, he became a Swiss Institute of Bioinformatics Group Leader, in 2017, he was elected to the National Research Council of the Swiss National Science Foundation, in 2021, he received the Cloëtta Prize for outstanding contributions to biomedical research, and in 2022, the Leenaards Prize for Biomedical Translational Research. He is also the co-founder of two Biotech companies (Genohm, Acquired by Agilent in 2018; and Alithea Genomics).

Listed skills include Genetics, Genomics, Molecular Biology, Bioinformatics, and 17 others.